vs
agilon health, inc.（AGL）与费森尤斯医疗（FMS）财务数据对比。点击上方公司名可切换其他公司
费森尤斯医疗的季度营收约是agilon health, inc.的3.5倍（$5.5B vs $1.6B）。费森尤斯医疗净利率更高（7.9% vs -12.0%，领先20.0%）。agilon health, inc.同比增速更快（3.1% vs -0.3%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
费森尤斯医疗是德国知名医疗保健企业，核心业务为肾脏透析服务，在全球运营4171家门诊透析中心，服务约34.54万名患者。公司主要为终末期肾病患者提供治疗服务，该类患者需终身每周接受3次透析治疗以维持生命。
AGL vs FMS — 直观对比
营收规模更大
FMS
是对方的3.5倍
$1.6B
营收增速更快
AGL
高出3.4%
-0.3%
净利率更高
FMS
高出20.0%
-12.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $5.5B |
| 净利润 | $-188.9M | $434.2M |
| 毛利率 | — | 27.4% |
| 营业利润率 | -12.3% | 11.7% |
| 净利率 | -12.0% | 7.9% |
| 营收同比 | 3.1% | -0.3% |
| 净利润同比 | -78.5% | 240.4% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGLFMS
| Q4 25 | $1.6B | $5.5B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | $5.5B | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
净利润AGLFMS
| Q4 25 | $-188.9M | $434.2M | ||
| Q3 25 | $-110.2M | — | ||
| Q2 25 | $-104.4M | — | ||
| Q1 25 | $12.1M | — | ||
| Q4 24 | $-105.8M | $127.6M | ||
| Q3 24 | $-117.6M | — | ||
| Q2 24 | $-30.7M | — | ||
| Q1 24 | $-6.1M | — |
毛利率AGLFMS
| Q4 25 | — | 27.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率AGLFMS
| Q4 25 | -12.3% | 11.7% | ||
| Q3 25 | -9.1% | — | ||
| Q2 25 | -8.3% | — | ||
| Q1 25 | -1.4% | — | ||
| Q4 24 | -7.1% | 5.1% | ||
| Q3 24 | -9.2% | — | ||
| Q2 24 | -2.9% | — | ||
| Q1 24 | -0.4% | — |
净利率AGLFMS
| Q4 25 | -12.0% | 7.9% | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | -7.5% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | -6.9% | 2.3% | ||
| Q3 24 | -8.1% | — | ||
| Q2 24 | -2.1% | — | ||
| Q1 24 | -0.4% | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $1.7B |
| 总债务越低越好 | $35.0M | — |
| 股东权益账面价值 | $126.7M | $15.4B |
| 总资产 | $1.3B | $33.5B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资AGLFMS
| Q4 25 | $173.7M | $1.7B | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $171.4M | — | ||
| Q1 25 | $136.9M | — | ||
| Q4 24 | $188.2M | $1.3B | ||
| Q3 24 | $148.2M | — | ||
| Q2 24 | $109.5M | — | ||
| Q1 24 | $111.7M | — |
总债务AGLFMS
| Q4 25 | $35.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AGLFMS
| Q4 25 | $126.7M | $15.4B | ||
| Q3 25 | $306.1M | — | ||
| Q2 25 | $408.9M | — | ||
| Q1 25 | $500.3M | — | ||
| Q4 24 | $471.0M | $17.0B | ||
| Q3 24 | $574.9M | — | ||
| Q2 24 | $676.6M | — | ||
| Q1 24 | $689.3M | — |
总资产AGLFMS
| Q4 25 | $1.3B | $33.5B | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.7B | $36.3B | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.3B | — |
负债/权益比AGLFMS
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $2.9B |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | — |
| 自由现金流率自由现金流/营收 | -1.5% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | — | 6.67× |
| 过去12个月自由现金流最近4个季度 | $-119.0M | — |
8季度趋势，按日历期对齐
经营现金流AGLFMS
| Q4 25 | $-20.5M | $2.9B | ||
| Q3 25 | $-18.2M | — | ||
| Q2 25 | $-35.1M | — | ||
| Q1 25 | $-32.0M | — | ||
| Q4 24 | $16.4M | $2.6B | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $-18.7M | — | ||
| Q1 24 | $-47.8M | — |
自由现金流AGLFMS
| Q4 25 | $-23.5M | — | ||
| Q3 25 | $-21.3M | — | ||
| Q2 25 | $-38.3M | — | ||
| Q1 25 | $-35.8M | — | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $-11.2M | — | ||
| Q2 24 | $-22.0M | — | ||
| Q1 24 | $-50.9M | — |
自由现金流率AGLFMS
| Q4 25 | -1.5% | — | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | -0.8% | — | ||
| Q2 24 | -1.5% | — | ||
| Q1 24 | -3.2% | — |
资本支出强度AGLFMS
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | — |
现金转化率AGLFMS
| Q4 25 | — | 6.67× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -2.64× | — | ||
| Q4 24 | — | 20.20× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
FMS
暂无分部数据
